



Introduction


Multiple myeloma(MM) is a plasma cell malignancy affecting primarily older adults. The management of elderly patients is challenging. Although bortezomib-melphalan-prednisone(VMP) regimens are widely used in transplant-ineligible patients, real-world data on their efficacy and safety remain limited. This study aims to evaluate the efficacy and safety of VMP-based regimens in elderly patients with MM.

Methods

- ✓ Retrospective study
- ✓ Inclusion criteria: Elderly and newly diagnosed MM patients treated with VMP
- ✓ Period of the study : 2019–2025
- ✓ Study setting: Fattouma Bourguiba University Hospital, Monastir, Tunisia.
- ✓ We used SPSS to analyse ORR, VGPR, and treatment-related adverse effects.

Results

✓ 53 Patients

✓ Sex distribution : H/F = 


✓ Median age = **72 years** [58–92]

✓ Among evaluable patients, **disease stages were predominantly advanced:**

- ISS stage $\geq$ II : 76 %
- R-ISS stage $\geq$ II in 72%

✓ . Extramedullary disease (EMD) was present in 19% of patients.

✓ VMP-based regimen was used as :



✓ The **median number of treatment cycles** was 7[2–11].

✓ The ORR was 55%

✓ At least a VGPR was achieved in 23% of cases

Table 1 : Subgroup Analysis of Overall Response Rate


According to Baseline Clinical and Biological Characteristics

	ORR	P
Initial renal impairment	34 %	0,007
Bone involvement	51 %	0,43
EMD +	50 %	0,43
PS $\geq$ 2	53 %	0,68
ISS $\geq$ 2	38 %	0,68

✓ Higher response rates were observed with first-line compared to second-line therapy (59% vs 43%; $P=0.299$).

✓ The most common treatment-emergent adverse were :

Treatment-emergent adverse events



Conclusion

VMP-based therapy shows acceptable safety and efficacy in elderly and transplant-ineligible patients with MM. ORR was significantly

influenced by renal function

Acknowledgments

We wish to express our sincere gratitude to all members of the **Clinical Hematology Department**, whose expertise, dedication, and commitment to patient care serve as a constant source of inspiration. Their daily efforts ensure high-quality care and support the advancement of research within our department. We extend special thanks to **Dr Mohamed Adnene Laatiri, Head of the Clinical Hematology Department**, for his exceptional leadership and continuous support.